Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations.

Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M.

J Cardiovasc Pharmacol Ther. 2004 Dec;9(4):227-41. Review.

PMID:
15678242
2.

Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.

Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, Elkayam U.

J Am Coll Cardiol. 1995 Dec;26(7):1575-80.

3.

Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis.

Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, Dunne R, Zalenski R.

Ann Emerg Med. 2007 Aug;50(2):144-52.

PMID:
17509731
4.

[Therapeutic effect of recombinant human brain natriuretic peptide for treatment of decompensated heart failure: comparison with nitroglycerin].

Xie CL, Meng SR, Wang W, Chen SM, Li P, Feng XG.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):839-42. Chinese.

5.
6.
7.

Hemodynamic action of captopril in coronary patients with heart failure tolerant to nitroglycerin.

Störk T, Eichstädt H, Möckel M, Gareis R, Bodemann T, Müller R.

Clin Cardiol. 1997 Dec;20(12):999-1004.

8.

Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.

Dakak N, Makhoul N, Merdler A, Yechiely H, Kahana L, Halon DA, Schneeweiss A, Lewis BS.

Eur Heart J. 1993 Jun;14(6):836-44.

PMID:
8325314
9.

Impact of intravenous nitroglycerin in the management of acute decompensated heart failure.

den Uil CA, Brugts JJ.

Curr Heart Fail Rep. 2015 Feb;12(1):87-93. doi: 10.1007/s11897-014-0230-8. Review.

PMID:
25301529
10.

Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure.

den Uil CA, Caliskan K, Lagrand WK, van der Ent M, Jewbali LS, van Kuijk JP, Spronk PE, Simoons ML.

Intensive Care Med. 2009 Nov;35(11):1893-9. doi: 10.1007/s00134-009-1591-4.

PMID:
19639300
11.

In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators.; ADHERE Study Group..

J Am Coll Cardiol. 2005 Jul 5;46(1):57-64.

12.

Prevention and reversal of nitrate tolerance in patients with congestive heart failure.

Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M.

N Engl J Med. 1987 Sep 24;317(13):799-804.

PMID:
3114637
13.
14.
15.

Tailored therapy using dobutamine and nitroglycerin in advanced heart failure.

Drazner MH, Solomon MA, Thompson B, Yancy CW.

Am J Cardiol. 1999 Oct 15;84(8):941-3, A7.

PMID:
10532519
16.

Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.

Parker JD, Bart BA, Webb DJ, Koren MJ, Siegel RL, Wang H, Malhotra B, Jen F, Glue P.

Crit Care Med. 2007 Aug;35(8):1863-8.

PMID:
17522570
18.
19.

Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.

Abraham WT, Cheng ML, Smoluk G; Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Study Group..

Congest Heart Fail. 2005 Mar-Apr;11(2):59-64.

20.
Items per page

Supplemental Content

Support Center